- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00280605
ALF-ONE : ALFuzosin ONcE Daily
August 30, 2010 updated by: Sanofi
Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China
The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Study Overview
Study Type
Interventional
Enrollment
200
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Ambulatory patients suffering from Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia
Exclusion Criteria:
- Patients requiring Benign Prostatic Hyperplasia surgery immediately or within the 12 following months
- Patients previously not improved by an alpha 1-blocker treatment
- Patients whose urinary symptoms are satisfactorily controlled on other Benign Prostatic Hyperplasia medication (alpha 1-blockers and 5-ARI)
- Known hypersensitivity to alfuzosin
- History of postural hypotension or syncope
- Combination with other alpha 1-blockers
- Hepatic insufficiency
- Unstable angina pectoris
- Severe concomitant condition threatening life
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Spontaneous adverse events
|
Blood pressure and heart rate measured in sitting position
|
International Prostate Symptom Score (IPSS) and quality of life index
|
DAN-PSS sexual function score
|
PSA levels measured at baseline
|
Maximum flow rate and residual urine
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Benedict Blayney, MD, Sanofi
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2005
Primary Completion (Actual)
February 1, 2006
Study Completion (Actual)
February 1, 2006
Study Registration Dates
First Submitted
January 20, 2006
First Submitted That Met QC Criteria
January 20, 2006
First Posted (Estimate)
January 23, 2006
Study Record Updates
Last Update Posted (Estimate)
August 31, 2010
Last Update Submitted That Met QC Criteria
August 30, 2010
Last Verified
August 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Prostatic Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Alfuzosin
Other Study ID Numbers
- PM_L_0168
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Hyperplasia
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
Assiut UniversityNot yet recruiting
-
NeoTract, Inc.Not yet recruitingBenign Prostatic Hyperplasia
-
Assiut UniversityNot yet recruitingBenign Prostatic Hyperplasia
-
Second Affiliated Hospital, School of Medicine,...RecruitingBenign Prostatic HyperplasiaChina
-
Jewish General HospitalNot yet recruitingBenign Prostatic Hyperplasia
-
Zenflow, Inc.RecruitingBenign Prostatic HyperplasiaAustralia, New Zealand
-
REMD Medical TechnologyRenJi Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Sun Yat-Sen... and other collaboratorsCompletedBenign Prostatic HyperplasiaChina
-
Bioaraba Health Research InstituteCompletedBenign Prostatic HyperplasiaSpain
Clinical Trials on Alfuzosin
-
Unity Health TorontoSanofiWithdrawn
-
SanofiCompleted
-
International Bio serviceNot yet recruiting
-
Singapore General HospitalSanofiWithdrawn
-
SanofiCompleted
-
Hospital Authority, Hong KongTerminatedProstatic Hyperplasia | Acute Disease | Urinary RetentionChina
-
Torrent Pharmaceuticals LimitedCompleted
-
University Hospitals Cleveland Medical CenterSanofiCompletedErectile Dysfunction | BPHUnited States
-
SanofiCompletedProstatic Hyperplasia | Urinary Retention | Benign Prostatic HypertrophyUnited States, Canada, Poland, Romania, Australia, Netherlands, Portugal, Spain, Sweden, Bulgaria, Denmark, Finland, Hungary, Norway, South Africa, Greece, Israel